Literature DB >> 6186866

Effects of in vivo beta-adrenoceptor down-regulation on cardiac responses to prenalterol and pirbuterol.

T P Kenakin, R M Ferris.   

Abstract

The effects of beta-adrenoceptor down-regulation on rat left atrial responses to the full agonist isoproterenol and the partial agonists prenalterol and pirbuterol were studied. Atria from rats implanted with a mini-osmotic-pump subcutaneously delivering isoproterenol at 400 micrograms X kg-1 X h-1 for 4 days were 12-16 times less sensitive to isoproterenol than normal atria. Scatchard analyses indicated that the implantation of these mini-osmotic-pumps produced a 50% decrease in the number of beta-adrenoceptors in the ventricles with no alteration in the binding constant of [3H]dihydroalprenolol. Receptor down-regulation produced a parallel shift to the right of concentration-response curves to isoproterenol, and a complete suppression of responses to both partial agonists. The affinities of the partial agonists for the receptors were not altered; in desensitized atria the partial agonists were functional beta-antagonists blocking the responses to isoproterenol. The data are modeled by equations from classical receptor theory which predict the depression of responses to partial agonists with receptor down-regulation. These results are discussed with respect to the utility of prenalterol and pirbuterol in congestive heart failure since possible tachyphylaxis to these drugs with chronic usage could limit their value.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6186866     DOI: 10.1097/00005344-198301000-00014

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  12 in total

Review 1.  Myocardial beta-adrenoceptor function and regulation in heart failure: implications for therapy.

Authors:  D B Barnett
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

2.  Functional analysis of desensitization of the beta-adrenoceptor signalling pathway in rat cardiac tissues following chronic isoprenaline infusion.

Authors:  L McMartin; R J Summers
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

Review 3.  Pirbuterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible bronchospastic disease.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-07       Impact factor: 9.546

4.  Effects of in vivo treatment with isoprenaline or prenalterol on beta-adrenoceptor mechanisms in the heart and soleus muscle of the cat.

Authors:  A Hedberg; H Mattsson; V Nerme; E Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-03       Impact factor: 3.000

5.  The putative melatonin receptor antagonist GR128107 is a partial agonist on Xenopus laevis melanophores.

Authors:  M T Teh; D Sugden
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

6.  Cardiovascular actions of OPC-18790: a novel positive inotropic agent with little chronotropic action.

Authors:  T Hosokawa; T Mori; H Fujiki; S Kinoshita; K Takemoto; T Imaizumi; T Noda; M Ohura; M Tominaga; Y Yabuuchi
Journal:  Heart Vessels       Date:  1992       Impact factor: 2.037

7.  A multicenter study of a new inotropic agent, piperanometozine (OPC-8212) in congestive heart failure: clinical improvement during short-term treatment.

Authors:  M Inoue; M Hori; H Yasuda; T Takishima; T Sugimoto; S Sasayama; T Sakurai; H Nonogi; K Kodama; R Kusukawa
Journal:  Cardiovasc Drugs Ther       Date:  1987-08       Impact factor: 3.727

8.  Effects of chronic intravenous infusions of dopexamine and isoprenaline to rats on D1-, beta 1- and beta 2-receptor-mediated responses.

Authors:  S W Martin; K J Broadley
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

9.  Pharmacology and inotropic potential of forskolin in the human heart.

Authors:  M R Bristow; R Ginsburg; A Strosberg; W Montgomery; W Minobe
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

10.  Positive inotropic effects of the calcium channel activator Bay K 8644 on guinea-pig and human isolated myocardium.

Authors:  M Näbauer; L Brown; E Erdmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-01       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.